18-Methyl-19-norandrost-4-ene 17, 17-spiro ether (18-methyl-19-nor-20-spirox-4-en-3-one), and pharmaceutical products comprising the same

US7846917B2 · kind B2 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Rolf Bohlmann · Berlin, DE
• Joachim Kuhnke · Leverkusen, DE
• Jan Huebner · Berlin, DE
• Norbert Gallus · Berlin, DE
• Frederik Menges · Schriesheim, DE
• Steffen Borden · Berlin, DE
• Hans-Peter Muhn · Berlin, DE
• Katja Prelle · Berlin, DE

Key dates

• Filing date: Jun 28, 2007
• Grant date: Dec 7, 2010
• Expiry date: Apr 10, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P15/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention describes the novel 18-methyl-19-norandrost-4-ene 17,17-spiro ethers of the general formula Iin which The novel compounds have progestational and antimineralocorticoid activity.